GENSOUS, Noemie; LAZARO, Estibaliz; BLANCO, Patrick; RICHEZ, Christophe

doi:10.1080/1744666X.2023.2268284

Métadonnées

Licence d’utilisation du document

GENSOUS, Noemie
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

LAZARO, Estibaliz

Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

BLANCO, Patrick
Immunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]

Langue

Article de revue

Ce document a été publié dans

Expert Review of Clinical Immunology. 2024, vol. 20, n° 1, p. 21 – 30

Résumé en anglais

Type 1 interferons (IFNs) play a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) and various type I IFNs targeting therapeutic approaches have been developed. Anifrolumab, a monoclonal antibody that binds to the subunit 1 of the type I IFN receptor, has acquired considerable interest and has entered different clinical human trials willing to evaluate its efficacy and safety. Areas covered: This review summarizes the data obtained in phases 1, 2, and 3 clinical trials of anifrolumab for SLE patients. A focus is made on data of clinical efficacy and safety obtained in MUSE, TULIP-1 and TULIP-2 trials. Expert opinion/Commentary: Anifrolumab is a promising therapeutic option for patients with SLE, currently authorized for moderate-to-severe SLE. Extensive real-world use is now going to generate data required to gain experience on the type of patients who benefit the most from the drug, and the exact positioning of anifrolumab in the therapeutic plan.< Réduire

Mots clés en anglais

Anifrolumab

COVID-19

Biologics

Cutaneous lupus erythematosus

Herpes zoster

Systemic lupus erythematosus

Type I interferons

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus

Langue

Ce document a été publié dans

Résumé en anglais

Mots clés en anglais

URI

DOI

Unités de recherche